Sanofi pulls the plug on ADC af­ter lung can­cer PhI­II dis­ap­points

The on­ly clin­i­cal-stage an­ti­body-drug con­ju­gate in Sanofi’s pipeline has flunked a Phase III study, push­ing the French drug­mak­er to wind down the en­tire de­vel­op­ment pro­gram.

At an in­ter­im analy­sis, the ADC failed to meet the dual pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival com­pared to do­c­etax­el in sec­ond-line metasta­t­ic non-squa­mous non-small cell lung can­cer. All pa­tients in the tri­al have tu­mors that ex­press high lev­els of car­ci­noem­bry­on­ic anti­gen-re­lat­ed cell ad­he­sion mol­e­cule 5 (CEA­CAM5), which the drug, tusami­ta­m­ab rav­tan­sine, is di­rect­ed against.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER